These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 14505664)

  • 1. Synthesis and evaluation of tripeptidyl alpha-ketoamides as human rhinovirus 3C protease inhibitors.
    Chen SH; Lamar J; Victor F; Snyder N; Johnson R; Heinz BA; Wakulchik M; Wang QM
    Bioorg Med Chem Lett; 2003 Oct; 13(20):3531-6. PubMed ID: 14505664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and synthesis of irreversible depsipeptidyl human rhinovirus 3C protease inhibitors.
    Webber SE; Marakovits JT; Dragovich PS; Prins TJ; Zhou R; Fuhrman SA; Patick AK; Matthews DA; Lee CA; Srinivasan B; Moran T; Ford CE; Brothers MA; Harr JE; Meador JW; Ferre RA; Worland ST
    Bioorg Med Chem Lett; 2001 Oct; 11(20):2683-6. PubMed ID: 11591501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis and evaluation of 2,2-dimethyl-1,3-dioxolane derivatives as human rhinovirus 3C protease inhibitors.
    Zhang Q; Cao R; Liu A; Lei S; Li Y; Yang J; Li S; Xiao J
    Bioorg Med Chem Lett; 2017 Sep; 27(17):4061-4065. PubMed ID: 28778471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and evaluation of 9-deoxy analogues of (-)-thysanone, an inhibitor of HRV 3C protease.
    Young Jeong J; Sperry J; Taylor JA; Brimble MA
    Eur J Med Chem; 2014 Nov; 87():220-7. PubMed ID: 25259514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis of the 2-methylene analogue of the HRV 3C protease inhibitor thysanone (2-carbathysanone).
    Schünemann K; Furkert DP; Choi EC; Connelly S; Fraser JD; Sperry J; Brimble MA
    Org Biomol Chem; 2014 Feb; 12(6):905-12. PubMed ID: 24346589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-based design of irreversible, tripeptidyl human rhinovirus 3C protease inhibitors containing N-methyl amino acids.
    Dragovich PS; Webber SE; Prins TJ; Zhou R; Marakovits JT; Tikhe JG; Fuhrman SA; Patick AK; Matthews DA; Ford CE; Brown EL; Binford SL; Meador JW; Ferre RA; Worland ST
    Bioorg Med Chem Lett; 1999 Aug; 9(15):2189-94. PubMed ID: 10465543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 6. Structure-activity studies of orally bioavailable, 2-pyridone-containing peptidomimetics.
    Dragovich PS; Prins TJ; Zhou R; Brown EL; Maldonado FC; Fuhrman SA; Zalman LS; Tuntland T; Lee CA; Patick AK; Matthews DA; Hendrickson TF; Kosa MB; Liu B; Batugo MR; Gleeson JP; Sakata SK; Chen L; Guzman MC; Meador JW; Ferre RA; Worland ST
    J Med Chem; 2002 Apr; 45(8):1607-23. PubMed ID: 11931615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. P4 cap modified tetrapeptidyl alpha-ketoamides as potent HCV NS3 protease inhibitors.
    Sun DX; Liu L; Heinz B; Kolykhalov A; Lamar J; Johnson RB; Wang QM; Yip Y; Chen SH
    Bioorg Med Chem Lett; 2004 Aug; 14(16):4333-8. PubMed ID: 15261297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery, total synthesis, HRV 3C-protease inhibitory activity, and structure-activity relationships of 2-methoxystypandrone and its analogues.
    Singh SB; Graham PL; Reamer RA; Cordingley MG
    Bioorg Med Chem Lett; 2001 Dec; 11(24):3143-6. PubMed ID: 11720861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and structure-activity relationship of α-keto amides as enterovirus 71 3C protease inhibitors.
    Zeng D; Ma Y; Zhang R; Nie Q; Cui Z; Wang Y; Shang L; Yin Z
    Bioorg Med Chem Lett; 2016 Apr; 26(7):1762-6. PubMed ID: 26916437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of quinone analogues as potential inhibitors of picornavirus 3C protease in vitro.
    Jung E; Lee JY; Kim HJ; Ryu CK; Lee KI; Kim M; Lee CK; Go YY
    Bioorg Med Chem Lett; 2018 Aug; 28(14):2533-2538. PubMed ID: 29866517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New 4-phenylcoumarin derivatives as potent 3C protease inhibitors: Design, synthesis, anti-HAV effect and molecular modeling.
    Kassem AF; Batran RZ; Abbas EMH; Elseginy SA; Shaheen MNF; Elmahdy EM
    Eur J Med Chem; 2019 Apr; 168():447-460. PubMed ID: 30844608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, and bioevaluation of viral 3C and 3C-like protease inhibitors.
    Prior AM; Kim Y; Weerasekara S; Moroze M; Alliston KR; Uy RA; Groutas WC; Chang KO; Hua DH
    Bioorg Med Chem Lett; 2013 Dec; 23(23):6317-20. PubMed ID: 24125888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peptidomimetic ethyl propenoate covalent inhibitors of the enterovirus 71 3C protease: a P2-P4 study.
    Ang MJ; Lau QY; Ng FM; Then SW; Poulsen A; Cheong YK; Ngoh ZX; Tan YW; Peng J; Keller TH; Hill J; Chu JJ; Chia CS
    J Enzyme Inhib Med Chem; 2016; 31(2):332-9. PubMed ID: 25792507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, and evaluation of nonpeptidic inhibitors of human rhinovirus 3C protease.
    Webber SE; Tikhe J; Worland ST; Fuhrman SA; Hendrickson TF; Matthews DA; Love RA; Patick AK; Meador JW; Ferre RA; Brown EL; DeLisle DM; Ford CE; Binford SL
    J Med Chem; 1996 Dec; 39(26):5072-82. PubMed ID: 8978838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and evaluation of pyrazolone compounds as SARS-coronavirus 3C-like protease inhibitors.
    Ramajayam R; Tan KP; Liu HG; Liang PH
    Bioorg Med Chem; 2010 Nov; 18(22):7849-54. PubMed ID: 20947359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conservation of amino acids in human rhinovirus 3C protease correlates with broad-spectrum antiviral activity of rupintrivir, a novel human rhinovirus 3C protease inhibitor.
    Binford SL; Maldonado F; Brothers MA; Weady PT; Zalman LS; Meador JW; Matthews DA; Patick AK
    Antimicrob Agents Chemother; 2005 Feb; 49(2):619-26. PubMed ID: 15673742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 3D-quantitative structure-activity relationship study for the design of novel enterovirus A71 3C protease inhibitors.
    Nie Q; Xu X; Zhang Q; Ma Y; Yin Z; Shang L
    Chem Biol Drug Des; 2018 Oct; 92(4):1750-1762. PubMed ID: 29877617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 8. Pharmacological optimization of orally bioavailable 2-pyridone-containing peptidomimetics.
    Dragovich PS; Prins TJ; Zhou R; Johnson TO; Hua Y; Luu HT; Sakata SK; Brown EL; Maldonado FC; Tuntland T; Lee CA; Fuhrman SA; Zalman LS; Patick AK; Matthews DA; Wu EY; Guo M; Borer BC; Nayyar NK; Moran T; Chen L; Rejto PA; Rose PW; Guzman MC; Dovalsantos EZ; Lee S; McGee K; Mohajeri M; Liese A; Tao J; Kosa MB; Liu B; Batugo MR; Gleeson JP; Wu ZP; Liu J; Meador JW; Ferre RA
    J Med Chem; 2003 Oct; 46(21):4572-85. PubMed ID: 14521419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and biological evaluation of α-ketoamides as inhibitors of the Dengue virus protease with antiviral activity in cell-culture.
    Steuer C; Gege C; Fischl W; Heinonen KH; Bartenschlager R; Klein CD
    Bioorg Med Chem; 2011 Jul; 19(13):4067-74. PubMed ID: 21641807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.